This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed the most recent trading day at $598.88, moving -0.07% from the previous trading session.
"Blockbuster Status": 3 Bios to Buy and Hold
by Andrew Rocco
The biotech sector is notorious for its sky-high R&D costs, regulatory hurdles, and lengthy timelines to bring a drug to market. Stock Strategist Andrew Rocco unveils 3 biotech stocks that have broken through and are set up for long term growth.
Altimmune (ALT) Rises 7% on Completing Dosing in Obesity Study
by Zacks Equity Research
Altimmune (ALT) completes the dosing of all patients in the mid-stage obesity study of pemvidutide. The company remains on track to announce top-line results in fourth-quarter 2023. The stock rises 7%.
Is First Trust Capital Strength ETF (FTCS) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FTCS
NVS vs. LLY: Which Stock Is the Better Value Option?
by Zacks Equity Research
NVS vs. LLY: Which Stock Is the Better Value Option?
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RSPH
Should You Invest in the Vanguard Health Care ETF (VHT)?
by Zacks Equity Research
Sector ETF report for VHT
Alector (ALEC) Up 7% on Finishing Enrolment in Alzheimer Study
by Zacks Equity Research
Alector (ALEC) completes enrolment in a mid-stage study evaluating its investigational monoclonal antibody in patients with early Alzheimer's disease. Data from the study is expected before year-end.
Zacks Investment Ideas feature highlights: IonQ, E.L.F Beauty, Amazon, Meta Platforms and Eli Lilly
by Zacks Equity Research
IonQ, E.L.F Beauty, Amazon, Meta Platforms and Eli Lilly are part of the Zacks Investment Ideas article.
Here's How Much You'd Have If You Invested $1000 in Eli Lilly a Decade Ago
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
4 Expert Tips for Navigating a Gap Down Market
by Andrew Rocco
Investors must learn to thrive in turbulent times. Stock Strategist Andrew Rocco provides 4 ways to hadle "tape bombs"
Prothena (PRTA) Skyrockets 88.7% in 12 Months: Here's Why
by Zacks Equity Research
Prothena (PRTA) gains a massive 88.7% in 12 months on pipeline progress with its AD candidates.
Why Is Lilly (LLY) Up 6.4% Since Last Earnings Report?
by Zacks Equity Research
Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should Franklin U.S. Large Cap Multifactor Index ETF (FLQL) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FLQL
Novo Nordisk (NVO) Launches Wegovy in UK Amid Supply Issues
by Zacks Equity Research
Novo Nordisk (NVO) announces the controlled and limited launch of Wegovy in the U.K. amid rising demand for weight loss treatment and supply constraints.
Should Invesco S&P 100 Equal Weight ETF (EQWL) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for EQWL
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Medicare's First Price Negotiation List Targets Expensive Drugs (Revised)
by Zacks Equity Research
The negotiations with participating drug companies are likely to happen in 2023 and 2024 with the negotiated prices, if any, going into effect in 2026.
Medicare's First Price Negotiation List Targets Expensive Drugs
by Kinjel Shah
The negotiations with participating drug companies are likely to happen in 2023 and 2024 with the negotiated prices, if any, going into effect in 2026.
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RSPH)?
by Zacks Equity Research
Sector ETF report for RSPH
Novo Nordisk's (NVO) Shares Jump 17% in a Month: Here's Why
by Zacks Equity Research
Novo Nordisk's (NVO) commercial and pipeline progress with its popular obesity drug, Wegovy, continues to drive the share price momentum.
If You Invested $1000 in Eli Lilly a Decade Ago, This is How Much It'd Be Worth Now
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FTCS
The Zacks Analyst Blog Highlights Eli Lilly, UnitedHealth, Walmart, Applied Materials and BCE
by Zacks Equity Research
Eli Lilly, UnitedHealth, Walmart, Applied Materials and BCE are included in this Analyst Blog.